By the end of this lesson
- Distinguish embryonic, adult and induced pluripotent stem cells.
- Explain potential medical uses and biological risks.
- Evaluate stem-cell use with a balanced, evidence-based conclusion.
BIG QUESTION
When does the possibility of repairing damaged tissue justify the biological and ethical risks of stem-cell treatment?
A sound judgement separates evidence about safety and effectiveness from ethical values, then weighs both in a defined medical context.
What makes a cell a stem cell?
A stem cellAn unspecialised cell that can divide to renew itself and can differentiate into one or more types of specialised cell. can self-renew by division and can differentiate into one or more specialised cell types. Potency describes the range of cell types it can produce.
Cells of the very early embryo can be totipotentDescribes a cell, such as one from a very early embryo, that can form all the embryonic cell types and the supporting (extra-embryonic) tissues needed for a complete organism., meaning they can form embryonic and supporting tissues. Embryonic stem-cell lines are generally pluripotentDescribes a stem cell, such as an embryonic stem cell, that can differentiate into almost any type of body cell but cannot form an entire organism.: they can form almost any body cell, but not an entire organism by themselves. Many adult stem cells are multipotentDescribes a stem cell, such as an adult stem cell in bone marrow, that can differentiate into only a limited range of related cell types. and form a narrower range.
Sources differ in potential and risk
embryonic stem cellAn unspecialised cell from an early embryo that can divide and differentiate into almost any type of body cell. can produce many cell types and proliferate extensively in culture, but obtaining them involves an embryo and raises ethical questions. Cells from another individual may also be recognised as foreign by the recipient’s immune system.
adult stem cellAn unspecialised cell in a body tissue, such as bone marrow, that can divide and differentiate into a limited range of cell types., such as blood-forming stem cells in bone marrow, maintain and repair particular tissues. They usually have a narrower differentiation range but may be collected from the patient, reducing rejection. Collection can be invasive and the cells may be difficult to grow.
induced pluripotent stem cellAn adult body cell that has been reprogrammed in the laboratory to behave like an embryonic stem cell, able to differentiate into many cell types. are adult body cells reprogrammed to a pluripotent state. They reduce the need for embryos and can be patient-matched, but reprogramming, genetic instability and tumour risk require careful control.
From possibility to treatment
Stem cells could replace cells lost through injury or disease—for example blood-forming cells after cancer treatment, insulin-producing cells in diabetes, retinal cells in some eye disease, or nerve cells after damage. A plausible cell type is not proof that a treatment is safe or effective.
Cells must differentiate into the correct type, survive, integrate with existing tissue and function in a controlled way. Uncontrolled division can form tumours; contamination or genetic abnormalities can cause harm.
Ethical and social questions
Ethical objections often concern the moral status of an embryo and whether it is acceptable to destroy an embryo for research or treatment. Other perspectives emphasise informed donation, embryos remaining after IVF, reduction of suffering and the possibility of saving lives.
Social questions include fair access, cost, regulation and misleading claims from unproven clinics. These are distinct from biological risks, although both affect a decision.
How to reach a justified judgement
An evaluation should name a specific use, compare relevant alternatives and weigh benefits against risks. It should also identify evidence that would change the decision, such as trial results, tumour frequency, immune rejection and long-term follow-up.
A conclusion can be conditional: use may be justified for a severe condition when established treatments fail, consent is informed, regulation is strong and evidence shows that benefits outweigh harms.
Comparing stem-cell sources
No source is simply “best”; suitability depends on the intended treatment.
| Source | Potential advantages | Limitations or concerns |
|---|---|---|
| Embryonic stem cells | Pluripotent; extensive self-renewal; can generate many body-cell types. | Embryo ethics, immune rejection, differentiation control and tumour risk. |
| Adult stem cells | Established uses such as bone-marrow transplantation; patient cells may reduce rejection. | Usually multipotent, sometimes difficult to isolate and expand, invasive collection. |
| Induced pluripotent stem cells | Pluripotent and potentially patient-matched without using an embryo. | Reprogramming may introduce abnormalities; differentiation and tumour risks remain. |
Language that earns precision
- stem cell
- A cell able to self-renew and differentiate into one or more specialised cell types.
- totipotent
- Able to form all embryonic and extra-embryonic cell types needed for a complete organism.
- pluripotent
- Able to form almost any body-cell type.
- multipotent
- Able to form a limited range of related cell types.
- immune rejection
- An immune response against transplanted cells recognised as non-self.
- clinical trial
- A controlled study in people used to evaluate safety and effectiveness.
Common misconceptions
Claim: All embryonic stem cells are totipotent.
Correction: Very early embryonic cells may be totipotent; established embryonic stem cells are usually pluripotent.
Claim: A possible stem-cell use is already a proven cure.
Correction: Potential treatments require evidence from controlled trials and long-term safety monitoring.
Claim: Patient-matched cells have no risks.
Correction: They may reduce immune rejection, but contamination, mutation, faulty differentiation and tumour risks remain.
Claim: Ethical objections are the same as biological disadvantages.
Correction: Ethics concerns values and rights; biological disadvantages concern safety and function. Both can inform a judgement.
Match the answer to the command word
State what the stem cells can do or how treatment would proceed.
Connect cell potency or matching to a medical benefit or risk.
Present relevant benefits and limitations, weigh them in context and finish with a justified conclusion.
Recall, apply, then justify
Recall, apply, then justify (continued)
Distinguish a pluripotent stem cell from a multipotent stem cell.
Hint
Compare the range of possible specialised cells.
Suggested marking points
- A pluripotent cell can form almost any body-cell type.
- A multipotent cell forms a limited range of related cell types.
Explain why patient-derived stem cells may be useful in transplantation.
Hint
Use genetic similarity and immune recognition.
Suggested marking points
- The cells are genetically matched to the patient.
- They are less likely to be recognised as foreign and rejected by the immune system.
Explain two biological risks of an embryonic stem-cell treatment.
Hint
Choose risks caused by cell behaviour or immune response, not ethical objections.
Suggested marking points
- Cells may divide uncontrollably and form a tumour.
- Cells may differentiate into the wrong type or fail to integrate.
- Donor cells may be recognised as foreign.
- An immune response may reject or damage the transplant.
Evaluate the use of embryonic stem cells to replace damaged nerve cells.
Hint
Balance potency and possible benefit against control, safety, rejection and ethics before concluding.
Suggested marking points
- They can differentiate into nerve cells and may replace cells with poor natural repair.
- This could restore some function or reduce disability.
- Differentiation and integration must be controlled.
- There are risks of tumours and immune rejection.
- Obtaining cells raises ethical concerns about embryo use.
- A justified, context-specific conclusion weighs disease severity and evidence of safety and effectiveness.
Design the evidence package you would require before approving a new patient-matched stem-cell treatment for clinical use.
Planning hint
Include identity, function, safety, comparison and time.
What a strong design includes
- Confirm that cells have differentiated into the intended type using appropriate markers.
- Demonstrate the required function in laboratory and preclinical models.
- Test genetic stability, contamination and uncontrolled growth.
- Measure immune response even if cells are patient-matched.
- Use controlled clinical trials against current best treatment where ethical.
- Include sufficient participants, clinically meaningful outcomes and long-term follow-up.
- Specify stopping rules and independent ethical and regulatory oversight.